ORIGINAL RESEARCH Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin

Koji Sugioka¹ Masahiko Fukuda¹ Shohei Komoto¹ Motoki Itahashi¹ Masakazu Yamada² Yoshikazu Shimomura¹

Department of Ophthalmology, Kinki University School of Medicine, Osaka-Sayama City, Osaka, Japan; ²Division for Vision Research, National Institute of Sensory Organs, National Tokyo Medical Center, Tokyo, Japan

Correspondence: Koji Sugioka Department of Ophthalmology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama City, Osaka, 589-8511 Japan Tel +81 72 366 0221 Fax +81 72 368 2559 Email sugioka@ganka.med.kindai.ac.jp **Purpose:** The objective of the study was to compare the intraocular penetration levels of the newer fluoroquinolones, moxifloxacin, gatifloxacin, and levofloxacin in the rabbit's cornea, aqueous humor, and conjunctiva after topical instillation.

Methods: 0.5% moxifloxacin, 0.3% gatifloxacin, and 0.5% levofloxacin were instilled in random sequence in both eyes of nine New Zealand White rabbits at two-minute intervals. Instillation was repeated every 15 minutes for a total of three drops of each fluoroquinolone per eye. Three additional animals had only moxifloxacin instilled bilaterally using the same schedule. Sixty minutes after the final instillation, the rabbits were sacrificed for determination of corneal, aqueous humor, and conjunctival fluoroquinolone concentrations using highperformance liquid chromatography.

Results: Moxifloxacin achieved significantly higher concentrations than levofloxacin and gatifloxacin in the cornea (P = 0.0102 and P = 0.0006, respectively), aqueous humor (P = 0.0015and P < 0.0001, respectively), and conjunctiva (P = 0.0191 and P = 0.0236, respectively). **Conclusions:** 0.5% moxifloxacin eyedrops provided superior intraocular penetration in rabbits' eyes compared with the two other fluoroquinolones, 0.5% levofloxacin and 0.3% gatifloxacin.

Keywords: fluoroquinolone, gatifloxacin, levofloxacin, moxifloxacin, penetration, rabbit

Introduction

Prophylactic antibiotic eye drops are routinely used to prevent postoperative infections. Fluoroquinolones in particular have been used extensively due to their excellent activity against ocular pathogens, including both Gram-positive and Gramnegative bacteria.^{1,2} Selection of the most appropriate antibiotic should be based on considerations of pharmacodynamic and pharmacokinetic properties; namely, an agent with a broader spectrum, lower minimum inhibitory concentration (MIC) against pathogens, and better achievable concentration levels in the intraocular tissues should be the agent of choice to achieve optimal efficacy. However, there are few studies that have clearly assessed the superiority of one drug over another among the newer fourth-generation fluoroquinolones, including moxifloxacin and gatifloxacin, when used in humans.

The current study was conducted to compare the penetration levels of new fluoroquinolones, including the fourth-generation fluoroquinolones (moxifloxacin and gatifloxacin) and a third-generation fluoroquinolone (levofloxacin) in the cornea, aqueous humor, and conjunctiva after topical instillation in New Zealand White rabbits. This animal study was performed as a preliminary step toward conducting a similar ocular penetration study in patients scheduled for keratoplasty.

which permits unrestricted noncommercial use, provided the original work is properly cited.

Materials and methods

Twelve New Zealand White rabbits were used to determine the concentration levels of three topically instilled fluoroquinolones in the cornea, aqueous humor, and conjunctiva. Topical preparations of 0.5% moxifloxacin (Vegamox, Alcon Japan, Tokyo, Japan), 0.3% gatifloxacin (Gatiflo, Senju Pharmaceuticals, Osaka, Japan) and 0.5% levofloxacin (Cravit, Santen Pharmaceuticals, Osaka, Japan) were obtained from the respective manufacturers.

The rabbits were randomly assigned to four treatment groups in accordance with the analytical method reported by Diamond and colleagues and Yamada and colleagues.^{3–5} One drop of each topical preparation was instilled in both eyes of each animal at two-minute intervals (Figure 1). In group 1, moxifloxacin was instilled first, followed by gatifloxacin two minutes later, and finally, levofloxacin after another two minutes. In group 2, gatifloxacin, and in group 3, levofloxacin, was instilled first, followed by moxifloxacin. In group 4, only moxifloxacin was instilled to compare the concentration levels with those in animals instilled with three different fluoroquinolones in order to verify that the levels were similar. Instillation was repeated every 15 minutes for a total of three drops of each fluoroquinolone

per eye. Sixty (60) minutes after the final instillation, the rabbits were sacrificed and corneal, aqueous humor, and conjunctival samples were collected from each eye.

The sample concentrations of each fluoroquinolone were simultaneously determined by high-performance liquid chromatography (HPLC) at the Mitsubishi BCL laboratory. A HPLC system consisting of a L-7000 solvent delivery system (Hitachi, Tokyo, Japan), a L-7485 fluorescence detector (Hitachi), and a chromatography software (Scientific Software Inc., Pleasanton, CA, USA) was used. The elution was performed using TSKgel ODS-80TM column (Tosoh Inc., Tokyo, Japan) at 40 °C with a mobile phase of 75:25 mixture of pH 3.0, 0.05M phosphoric acid and acetonitrile. Flow rate was 0.8 mL/min and detection was by fluorescence (excitation 290 nm, emission 470 nm) using a fluorescence detector. Drug concentrations were determined against a calibration line constructed from known aqueous drug concentrations.

Tukey's multiple pair-wise comparison was employed for between-group comparisons. A P value of less than 0.05 was considered statistically significant.

Results

A typical chromatogram is shown in Figure 2. The mean retention times of levofloxacin, gatifloxacin, and moxifloxacin




Figure I Treatment schedule.

‡ 2 minutes.

Abbreviations: MFLX, moxifloxacin; GFLX, gatifloxacin; LVFX, levofloxacin.




Figure 2 High-performance liquid chromatogram of moxifloxacin, levofloxacin, and gatifloxacin.

were 5.089 minutes, 7.019 minutes and 9.495 minutes, respectively.

As shown on Table 1, in the 18 corneas of nine animals (excluding the moxifloxacin alone group), the mean concentration of moxifloxacin ($12.23 \pm 5.33 \ \mu g/g$) was significantly higher than either levofloxacin ($7.34 \pm 1.88 \ \mu g/g$, P = 0.0102) or gatifloxacin ($6.32 \pm 2.47 \ \mu g/g$, P = 0.0006). The aqueous humor of 18 eyes of nine animals demonstrated that moxifloxacin had a significantly higher mean concentration ($2.677 \pm 1.094 \ \mu g/mL$) compared with levofloxacin ($1.511 \pm 0.401 \ \mu g/mL$, P = 0.0015) and gatifloxacin

(1.112 ± 0.438 µg/mL, P < 0.0001). In the conjunctiva (18 eyes of nine animals), mean moxifloxacin concentration (3.15 ± 1.60 µg/g) was significantly higher than either levofloxacin (1.77 ± 0.97 µg/g, P = 0.0191) or gatifloxacin (1.84 ± 0.94 µg/g,P = 0.0236). There were no statistically significant differences between levofloxacin and gatifloxacin in any of the samples (cornea, aqueous humor, or conjunctiva).

No significant differences were observed among groups of different instillation order. Mean fluoroquinolone concentrations were comparable, regardless of the order

Tissue	Drug	Group I mean±SD (n=6)	Group 2 mean ± SD (n = 6)	Group 3 mean ± SD (n = 6)	Group 4 mean ± SD (n = 6)	Group I–3 mean ± SD (n = 18)	P value* vs MFLX
Cornea	MFLX (µg/g)	$\textbf{7.85} \pm \textbf{4.14}$	15.39 ± 5.88	$\textbf{I3.46} \pm \textbf{2.83}$	12.55 ± 3.48	12.23 ± 5.33	_
	LVFX (µg/g)	$\textbf{7.75} \pm \textbf{2.21}$	$\textbf{7.57} \pm \textbf{2.38}$	6.71 ± 0.83	-	$\textbf{7.34} \pm \textbf{1.88}$	0.0102
	GFLX (µg/g)	$\textbf{4.64} \pm \textbf{0.91}$	5.99 ± 1.39	$\textbf{8.32} \pm \textbf{3.10}$	-	$\textbf{6.32} \pm \textbf{2.47}$	0.0006
Aqueous humor	MFLX (µg/mL)	$\textbf{2.022} \pm \textbf{1.250}$	2.876 ± 1.169	3.022 ± 0.771	$\textbf{2.335} \pm \textbf{0.714}$	$\textbf{2.677} \pm \textbf{1.094}$	-
	LVFX (µg/mL)	$\textbf{1.652} \pm \textbf{0.508}$	$\textbf{1.483} \pm \textbf{0.478}$	$\textbf{1.423} \pm \textbf{0.225}$	-	1.511 ± 0.401	0.0015
	GFLX (µg/mL)	$\textbf{0.887} \pm \textbf{0.206}$	$\textbf{1.004} \pm \textbf{0.236}$	$\textbf{1.407} \pm \textbf{0.596}$	-	$\textbf{1.112} \pm \textbf{0.438}$	<0.0001
Conjunctiva	MFLX (µg/g)	2.11 ± 1.23	$\textbf{3.97} \pm \textbf{2.03}$	3.49 ± 1.14	$\textbf{3.07} \pm \textbf{1.31}$	$\textbf{3.15} \pm \textbf{1.60}$	-
	LVFX (µg/g)	$\textbf{2.49} \pm \textbf{1.27}$	$\textbf{1.24} \pm \textbf{0.60}$	$\textbf{1.48} \pm \textbf{0.38}$	-	$\textbf{1.77} \pm \textbf{0.97}$	0.0191
	GFLX (µg/g)	$\textbf{1.49} \pm \textbf{0.82}$	$\textbf{1.34} \pm \textbf{0.58}$	$\textbf{2.61} \pm \textbf{0.87}$	-	$\textbf{I.84} \pm \textbf{0.94}$	0.0236

Table I Mean concentration of 0.5% moxifloxacin, 0.5% levofloxacin, and 0.3% gatifloxacin in the cornea, aqueous humor, and conjunctiva

*Tukey's multiple pair-wise comparison.

of instillation. The mean concentrations of moxifloxacin in each tissue in group 4 (moxifloxacin alone) were nearly identical to those in groups 1, 2, and 3.

Discussion

Perioperative antibiotics should have several therapeutic attributes. Ideal agents should have a broad spectrum of antibacterial activity, high potency against pathogenic organisms, and favorable penetration characteristics to deliver the antibiotic to the target ocular tissues. It is particularly important to consider the ability to achieve a concentration well above the MIC for microorganisms. The present study showed that mean concentrations of moxifloxacin were significantly higher than the two other fluoroquinolones in all three intraocular sites tested. These results are comparable to those previously reported by Yamada and colleagues and others.³⁻⁶ The concentration of each fluoroquinolone used in this study, however, was not uniform, given that the gatifloxacin preparation was a 0.3% solution, while moxifloxacin and levofloxacin were administrated as 0.5% solutions. This is because commercially available eyedrops were used in the study to mimic the clinical situation.

Besides the difference in concentrations of fluroquinolones tested, the present results can be logically explained from the viewpoint of the physical properties of the respective fluoroquinolones. Moxifloxacin is highly hydrophilic and lipophilic; the hydrosolubility of moxifloxacin is more than 6%, while that of gatifloxacin and levofloxacin is 0.21% and 1.85%, respectively. The liposolubility of moxifloxacin is 0.24 $(C-7, \delta)$, while that of gatifloxacin and levofloxacin is 0.11 and 0.06, respectively.^{7,8} Such disparities in the physical properties of these fluoroquinolones lead to differences in their ocular penetration. The corneal permeability of moxifloxacin is 15.8×10^7 cm/sec, while that of gatifloxacin and levofloxacin is 4.6×10^7 cm/sec and 6.95×10^7 cm/sec, respectively. Such properties of moxifloxacin are thought to be due to its chemical structure, which comprises a large pyrrolo-pyridine group chain at the C7 position of the basic quinolone structure, conferring hydrophilicity along with lipophilicity.⁷

Based on the findings from the current animal study, a similar clinical study using patients scheduled for keratoplasty is planned. The drugs used and the application schedule will be identical to the present study, and samples will be collected during surgery for drug concentration determination. Although animals are typically randomized into three different treatment groups in studies comparing three distinct eye drops, the present study design, in which three different eye drops are nearly simultaneously instilled into the animals' eyes, offers the advantage that a single specimen can yield three drug concentrations because HPLC can distinguish the different drugs. Individual differences in specimen permeability can make it difficult to compare the concentrations of different eye drops using traditional study design; however, the present method overcomes such problems, and allows the drugs to be compared within one specimen.

Before proceeding to a human study, some issues that may limit the interpretation of the current results should be reviewed. Since the time to maximum concentration in the aqueous humor (AQT_{max}) differs according to each agent, the timing of instillation is critical.9,10 The present study may have missed AQT_{max} of one or more of the study medications. The second issue is whether the concentrations of other agents might increase as a consequence of moxifloxacin in a group where moxifloxacin is instilled first since there is substantial penetration of moxifloxacin into the intraocular tissue. The third issue is whether a two-minute interval is optimal, since some investigators recommend a five-minute interval or at least a three-minute interval when investigating the efficacy of a particular agent. Although a two-minute interval is supported by a report showing that concentration levels in the anterior chamber did not differ when steroid eye drops were instilled at two-minute intervals,¹¹ the controversy remains. Our results also support the use of a two-minute interval, as no difference in concentrations was found among all four treatment groups, including the group which received only moxifloxacin.

Conclusion

In this study, topically applied 0.5% moxifloxacin achieved higher concentrations in cornea, aqueous humor and conjunctiva than 0.5% levofloxacin and 0.3% gatifloxacin in rabbit eyes. However, future penetration studies in humans as well as clinical studies using patients with ocular infections would reveal the differences in clinical efficacy among fluoroquinolones.

Acknowledgments

Editorial assistance was provided by Jennifer Klem, PhD, a freelance medical writer. This assistance was supported by Alcon Research, Ltd. The authors report no conflicts of interest in this work.

References

- 1. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. *Am J Ophthalmol.* 2002;133(4):463–466.
- Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. *Am J Ophthalmol.* 2003;136(3):500–505.

- Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. *Br J Ophthalmol.* 1995;79(6):606–609.
- Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes. *J Cataract Refract Surg.* 2003; 29(9):1771–1775.
- Yamada M, Ishikawa K, Mochizuki H, Kawai M. Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes. *Acta Ophthalmol Scand*. 2006;84(2): 192–196.
- 6. Yagci R, Oflu Y, Dincel A, et al. Penetration of second, third, and fourth generation topical flouroquinolone into aqueous and vitreous humor in a rabbit endophlamitis model. *Eye*. 2007;21(7):990–994.

- Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. *Surv Ophthalmol.* 2005;50(Suppl 1):S32–S45.
- Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into the anterior chamber. *Nippon Ganka Gappai Zasshi*. 1995;99(5):532–536.
- Fukuda M, Sasaki H. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions. *Curr Med Res Opin.* 2008; 24(12):3479–3486.
- Fukuda M, Sasaki K. General purpose antimicrobial ophthalmic solutions evaluated using new pharmacokinetic parameter of maximum drug concentration in aqueous. *Jpn J Ophthalmol.* 2002;46(4):384–390.
- Leibowitz HM, Kupferman A. Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis. *Arch Ophthalmol.* 1977;95(4):682–685.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Dovepress